Author:
Charalambous Andriani,Schwarzbich Mark-Alexander,Witzens-Harig Mathias
Publisher
Springer International Publishing
Reference129 articles.
1. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31
2. Ahn IE, Underbayev C, Albitar A, Herman SEM, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A (2017) Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129(11):1469–1479
3. Arthurs B, Wunderle K, Hsu M, Kim S (2017) Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep 21:27–29
4. Asnani A, Manning A, Mansour M, Ruskin J, Hochberg EP, Ptaszek LM (2017) Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-Oncology 3(1):2
5. Barbosa CC, DeAngelis LM, Grommes C (2017) Ibrutinib associated infections: a retrospective study. J Clin Oncol 35(15_suppl):e19020–e19020
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献